Cited 5 time in
Identification of Myoferlin Expression for Prediction of Subsequent Primary Malignancy in Patients With Clear Cell Renal Cell Carcinoma
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Koh, Hyun Min | - |
| dc.contributor.author | An, Hyo Jung | - |
| dc.contributor.author | Ko, Gyung Hyuck | - |
| dc.contributor.author | Lee, Jeong Hee | - |
| dc.contributor.author | Lee, Jong Sil | - |
| dc.contributor.author | Kim, Dong Chul | - |
| dc.contributor.author | Seo, Deok Ha | - |
| dc.contributor.author | Song, Dae Hyun | - |
| dc.date.accessioned | 2022-12-26T14:47:10Z | - |
| dc.date.available | 2022-12-26T14:47:10Z | - |
| dc.date.issued | 2019-07 | - |
| dc.identifier.issn | 0258-851X | - |
| dc.identifier.issn | 1791-7549 | - |
| dc.identifier.uri | https://scholarworks.gnu.ac.kr/handle/sw.gnu/8985 | - |
| dc.description.abstract | Background/Aim: Multiple primary malignant tumors are common in patients with renal cell carcinoma. However, reports on the factors that can identify patients with a risk for subsequent primary malignancies have been lacking. This study aimed to investigate whether myoferlin expression can be used as a potential marker to predict subsequent primary malignancies in patients with clear cell renal cell carcinoma (ccRCC). Materials and Methods: We evaluated the relationship of subsequent primary malignancies with clinicopathological factors and myoferlin expression in 152 patients with ccRCC, and we analyzed the strength of the association with myoferlin expression. Results: The development of subsequent primary malignancies exhibited significant correlation with patient age (p=0.029), sex (p=0.015), T stage (p<0.001), and myoferlin expression (p=0.017). Furthermore, myoferlin hyperexpression was determined as an independent risk factor for developing a subsequent primary malignant tumor in patients with ccRCC (odds ratio(OR), 2.485, 95% Confidence Interval(CI)= 1.052-5 .870, p=0.038). Conclusion: Myoferlin hyperexpression can be a useful marker for predicting the development of subsequent primary malignancies in patients with ccRCC. | - |
| dc.format.extent | 6 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | International Institute of Anticancer Research | - |
| dc.title | Identification of Myoferlin Expression for Prediction of Subsequent Primary Malignancy in Patients With Clear Cell Renal Cell Carcinoma | - |
| dc.type | Article | - |
| dc.publisher.location | 그리이스 | - |
| dc.identifier.doi | 10.21873/invivo.11579 | - |
| dc.identifier.scopusid | 2-s2.0-85069287682 | - |
| dc.identifier.wosid | 000474906500012 | - |
| dc.identifier.bibliographicCitation | In Vivo, v.33, no.4, pp 1103 - 1108 | - |
| dc.citation.title | In Vivo | - |
| dc.citation.volume | 33 | - |
| dc.citation.number | 4 | - |
| dc.citation.startPage | 1103 | - |
| dc.citation.endPage | 1108 | - |
| dc.type.docType | Article | - |
| dc.description.isOpenAccess | Y | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | Research & Experimental Medicine | - |
| dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
| dc.subject.keywordPlus | MULTIPLE PRIMARY MALIGNANCIES | - |
| dc.subject.keywordAuthor | Carcinoma | - |
| dc.subject.keywordAuthor | clear cell | - |
| dc.subject.keywordAuthor | kidney | - |
| dc.subject.keywordAuthor | myoferlin | - |
| dc.subject.keywordAuthor | subsequent primary malignancy | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Gyeongsang National University Central Library, 501, Jinju-daero, Jinju-si, Gyeongsangnam-do, 52828, Republic of Korea+82-55-772-0532
COPYRIGHT 2022 GYEONGSANG NATIONAL UNIVERSITY LIBRARY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
